Greenwich LifeSciences to Join Russell 2000 and 3000 Indexes in July

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024.
 

CEO Snehal Patel commented, "The addition of our company to the Russell 2000 Index may further increase our institutional ownership as it did in 2021 and is a reflection of the progress we have made in expanding FLAMINGO-01 into Europe and into up to 150 clinical sites globally."